Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GB221 vs Herceptin
NCT04175171Phase 1Completed
- Sponsor
- Genor Biopharma
- Start
- Nov 2011
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of coprelotamab in breast cancer (2 arms), sponsored by Genor Biopharma. Primary endpoints: Physical Examination up to 84 days, Adverse Events up to 84 days and 5 more. Started Nov 2011; status: completed.
02
Drugs
coprelotamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04175171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04175171.